Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) received its first Korean composition-of-matter patent (No. 10-2960889) for its breast cancer vaccine, granting exclusive protection in South Korea through 2040.

The patent, licensed from Cleveland Clinic, extends Anixa’s global IP estate and supports ongoing U.S. clinical development after a Phase 1 trial showed immune responses in 74% of participants.

Positive

• Korean breast cancer vaccine patent protection secured through 2040
• Patent issued by Korean MOIP complements U.S. and other international patents
• Vaccine technology exclusively licensed from Cleveland Clinic
• Phase 1 trial met all major primary endpoints and was well tolerated
• Immune responses observed in 74% of Phase 1 participants
• Expanded IP estate may support future regulatory, partnership and commercialization efforts

Negative

• Breast cancer vaccine remains in early-stage development, with only Phase 1 completed
• No preventive breast cancer vaccine is currently approved anywhere in the world

News Market Reaction – ANIX

+2.15%

8 alerts

+2.15% Session close to close

-12.2% Trough in 5 hr 13 min

$96.97M Market Cap

0.7x Rel. Volume

In the Jun 29 session, ANIX gained 2.15%, reflecting a moderate positive market reaction. Argus tracked a trough of -12.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends Korean composition-of-matter patent protection through 2040 and builds on ...

Analysis

This announcement extends Korean composition-of-matter patent protection through 2040 and builds on Phase 1 data showing 74% immune responses. With an active S-3 shelf and ATM capacity near $97M, investors may watch how IP gains translate into partnerships and trial progress.

Key Figures

Immune response rate: 74% of participants Phase 1 sample size: 35 participants Quarterly net loss: $2.5 million +5 more

8 metrics

Immune response rate 74% of participants Phase 1 breast cancer vaccine trial at Cleveland Clinic

Phase 1 sample size 35 participants Breast cancer vaccine Phase 1 trial

Quarterly net loss $2.5 million Quarter ended April 30, 2026

Six-month net loss $5.1 million Six months ended April 30, 2026

Cash balance $13.7 million As of April 30, 2026

ATM proceeds raised $2.9 million Six months ended April 30, 2026

Remaining ATM capacity $97 million Available under at-the-market stock offering

Dilution per share $1.29 Dilution to new investors in S-3 shelf prospectus

Historical Context

5 past events · Latest: Jun 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 26	Clinical data update	Positive	+6.5%	Updated positive Phase 1 data for breast cancer vaccine and ovarian CAR-T.
Jun 11	Symposium presentation	Positive	+5.5%	Announcement of presentations for two immunotherapy programs at NYAS meeting.
Jun 01	Patent allowance	Positive	+0.0%	Canadian notice of allowance for ovarian cancer vaccine patent technology.
May 11	CAR-T trial update	Positive	+1.0%	Updated survival and safety observations from Phase 1 lira-cel CAR-T trial.
May 11	Correction filing	Positive	+1.0%	Corrected report reiterating favorable survival and safety data for lira-cel.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinical and IP-focused announcements have generally coincided with modestly positive or flat price reactions.

Key Terms

composition of matter patent, cancer immunotherapy, α-lactalbumin, triple-negative breast cancer

4 terms

composition of matter patent regulatory

"Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine"

A composition of matter patent is a legal right that protects a specific chemical, molecule, material or formulated mixture—think of it as locking down a unique recipe for a substance. For investors it matters because the patent can give a company exclusive control to make, sell, or license that substance, creating a potential source of revenue and a competitive barrier similar to owning the only map to a valuable resource.

cancer immunotherapy medical

"reinforcing its leadership in the field of cancer immunotherapy."

Cancer immunotherapy is a group of treatments that help the body’s immune system recognize and attack cancer cells, like training the body’s soldiers to spot a hidden enemy. It matters to investors because these therapies can transform patient outcomes and create large markets if shown safe and effective, so clinical trial results, regulatory approvals, and manufacturing scale can drive significant changes in a company’s revenue and stock value.

α-lactalbumin medical

"Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation"

α-lactalbumin is a naturally occurring protein found in mammalian milk that supplies essential building blocks and supports nutrient absorption; think of it as a concentrated, high-quality protein ingredient used to boost the nutritional value of infant formula, medical nutrition and some supplements. Investors care because its use, purity, and supply affect product claims, regulatory approvals, patent positions and consumer demand in nutrition and health markets—factors that influence revenue and margins.

triple-negative breast cancer medical

"particularly in aggressive forms of the disease such as triple-negative breast cancer."

Triple-negative breast cancer is a type of breast cancer that lacks three common markers used to identify and treat the disease effectively. Because it doesn’t respond to some targeted therapies, it can be more difficult to treat and may have a more aggressive progression. This impacts the development of new treatments and can influence the outlook for healthcare companies involved in cancer research and pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate

Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients

SAN JOSE, Calif., June 29, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued Patent Number 10-2960889 related to Anixa's breast cancer vaccine technology. This composition-of-matter patent, exclusively licensed from Cleveland Clinic, protects the Company's novel approach to breast cancer prevention and treatment in South Korea through 2040, addressing a disease for which no preventive vaccine is currently approved anywhere in the world.

With this issued patent, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Korean patent complements Anixa's existing patent portfolio in the United States and other key international markets, further strengthening the Company's global intellectual property estate. The expanded patent protection enhances Anixa's ability to pursue future regulatory approvals, strategic partnerships and commercialization opportunities.

"Each global patent we secure deepens the global foundation we are building for our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization. In our recently completed Phase 1 clinical trial conducted at Cleveland Clinic, the vaccine met all major primary endpoints, was safe and well tolerated, and generated immune responses in 74% of participants, supporting continued clinical development of this novel preventive approach."

Breast cancer remains the most commonly diagnosed cancer among women worldwide, and currently there is no approved vaccine to prevent it. While breast cancer survival rates are high in South Korea, the incidence rate has been increasing rapidly and, unlike in Western nations, the disease tends to occur earlier in life heightening the need for preventive options in the region.

Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue, particularly in aggressive forms of the disease such as triple-negative breast cancer.

By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company's broader vaccine platform also targets other high-incidence cancers and is designed to transform how the medical community approaches cancer prevention. If successful, the technology could represent one of the first preventive vaccine approaches targeting breast cancer, representing a potentially transformative advancement in cancer prevention.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-granted-first-korean-patent-for-its-breast-cancer-vaccine-extending-global-protection-through-2040-302812489.html

SOURCE Anixa Biosciences, Inc.

FAQ

What did Anixa Biosciences (NASDAQ: ANIX) announce about its Korean breast cancer vaccine patent?

Anixa announced a new Korean composition-of-matter patent for its breast cancer vaccine, providing protection through 2040. According to Anixa, this patent from the Korean MOIP strengthens its global intellectual property estate and supports future regulatory, partnership and commercialization strategies for the vaccine platform.

How long does Anixa’s Korean breast cancer vaccine patent protect ANIX technology?

The Korean patent protects Anixa’s breast cancer vaccine technology in South Korea through 2040. According to Anixa, this long-term composition-of-matter coverage enhances exclusivity in a market with rising breast cancer incidence and earlier-age onset, supporting potential future commercialization and partnership discussions.

What were the Phase 1 trial results for Anixa’s breast cancer vaccine (ANIX)?

Anixa reported that its Phase 1 breast cancer vaccine trial met all major primary endpoints. According to Anixa, the Cleveland Clinic study showed the vaccine was safe, well tolerated, and generated immune responses in 74% of participants, supporting continued clinical development of this preventive approach.

Is there an approved preventive breast cancer vaccine as of Anixa’s June 29, 2026 update?

According to Anixa, no preventive breast cancer vaccine is currently approved anywhere in the world. The company’s Korean patent and Phase 1 data support ongoing efforts to develop an α-lactalbumin-based vaccine that could potentially offer a new preventive option in the future.

How does the Korean patent affect Anixa Biosciences’ global IP strategy for ANIX?

The Korean patent expands Anixa’s international intellectual property coverage for its breast cancer vaccine. According to Anixa, it complements existing patents in the United States and other markets, reinforcing the company’s ability to pursue global development, regulatory approvals and potential pharmaceutical partnerships.

What science underlies Anixa’s breast cancer vaccine covered by the Korean patent?

Anixa’s vaccine targets human α-lactalbumin, a lactation protein aberrantly expressed in certain breast cancers. According to Anixa, this “retired” protein strategy aims to prime the immune system to prevent tumor formation while sparing normal tissue, including aggressive subtypes like triple-negative breast cancer.